20/20 Biolabs, Inc. AIDX

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $2.05M · Filed Mar 31, 2026

20/20 Biolabs, Inc. (AIDX) files with the SEC under industry code 8734, Services-Testing Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $2.0 million and a net loss of $3.7 million. As of Jun 30, 2026 it held $4.5 million in cash and investments and $572,448 in total debt.

Revenue
$2.05M
Net income
$-3.74M
Operating cash flow
$-1.92M
Free cash flow
—
EPS
$-0.76
Dividend per share
None
Shares outstanding
10.44M
Net cash
$3.97M
as of Jun 30, 2026
Operating margin
-162.9%
FY 2025

Company profile

Industry
Services-Testing Laboratories (SIC 8734)
Listed as
AIDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Rockville, MD
SEC filer status
, Emerging growth company
SEC CIK
1139685
Former names
20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)

Other Services-Testing Laboratories companies

All 4 Services-Testing Laboratories companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Revenue
$2.0M
Operating income
-$3.3M
Net income
-$3.7M
Diluted EPS
-$0.76
Operating cash flow
-$1.9M
Total assets
$4.1M
Total liabilities
$4.2M
Stockholders' equity
-$19,225
Cash and investments
$1.0M
Total debt
$664,673

Recent SEC filings

Form Description Filed Period
8-K Current report
Shareholder vote results
 Sep 18, 2026 Sep 16, 2026
8-K Current report
Listing notice
 Sep 10, 2026 Sep 3, 2026
8-K Current report
Regulation FD disclosure
 Sep 2, 2026 Sep 2, 2026
8-K Current report
Shareholder vote results
 Aug 19, 2026 Aug 18, 2026
8-K Current report
Results of operations
 Aug 17, 2026 Aug 17, 2026
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026

All 167 20/20 Biolabs, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.